What is the role of combined thalidomide and lenalidomide (Revlimid) in the treatment of multiple myeloma (MM)?

Updated: Mar 06, 2020
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

An analogue of thalidomide, lenalidomide (Revlimid) is now a standard component of MM therapy. In July 2013, Celgene Corp announced that a phase III trial of lenalidomide (Revlimid) met the main goal of improving progression-free survival in patients with newly diagnosed MM. [50] The drug was already approved for use in previously-treated MM, mantle cell lymphoma, and transfusion-dependent anemia caused by myelodysplastic syndromes.

In the late-stage study, treatment with lenalidomide combined with dexamethasone in patients with newly diagnosed MM resulted in significantly longer survival without the cancer worsening, than did treatment with a regimen consisting of melphalan, prednisone, and thalidomide (MPT). [50]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!